Literature DB >> 16783456

Prevalence and clinical features of Clostridium difficile-associated diarrhea in a tertiary hospital in northern Taiwan.

Meng Shiuan Hsu1, Jann Tay Wang, Wen Kuei Huang, Yung Ching Liu, Shan Chwen Chang.   

Abstract

BACKGROUND AND
PURPOSE: Although the clinical manifestations of and risk factors for Clostridium difficile-associated diarrhea (CDAD) have been extensively investigated in western populations, data from Taiwanese patients are comparatively limited. This study investigated the incidence density of CDAD in Taiwanese patients and also the risk factors and clinical manifestations of CDAD.
METHODS: From September 21, 2003 to December 21, 2003, patients hospitalized in 2 infection wards and 6 medical intensive care units at National Taiwan University Hospital who were older than 20 years, had a history of antibiotic usage within the prior 6 weeks, and developed diarrhea without another identified etiology were classified as having antibiotic-associated diarrhea (AAD), and were enrolled for further study. The diagnosis of CDAD was established when toxin A of C. difficile was detected in stool.
RESULTS: The incidence density of AAD was 1/100 person-days of antibiotics usage. CDAD accounted for 12.5% of AAD. Fever and abdominal discomfort developed in only less than half of CDAD patients. Pus cell in the stool sample was found in 100 percent of patients with CDAD. Univariate analysis revealed that presence of malignancy and treatment with antifungal agents within the previous 6 weeks were risk factors for CDAD development. In multivariate analysis, use of antifungal agents was the only independent risk factor for CDAD.
CONCLUSION: The incidence density of CDAD in this study of Taiwanese patients with AAD was 12.5%. Prior usage of antifungal agents was the only independent factor associated with subsequent CDAD development in patients with AAD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16783456

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  13 in total

Review 1.  The role of fungi in C. difficile infection: An underappreciated transkingdom interaction.

Authors:  David Stewart; Jesus A Romo; Regina Lamendella; Carol A Kumamoto
Journal:  Fungal Genet Biol       Date:  2019-04-10       Impact factor: 3.495

2.  Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens.

Authors:  D R Snydman; N V Jacobus; L A McDermott
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

3.  Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.

Authors:  Chun-Hsing Liao; Wen-Chien Ko; Jang-Jih Lu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

4.  Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan.

Authors:  Yi-Chun Lin; Yu-Tsung Huang; Pei-Jane Tsai; Tai-Fen Lee; Nan-Yao Lee; Chun-Hsing Liao; Shyr-Yi Lin; Wen-Chien Ko; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

5.  Pre-colonization with the commensal fungus Candida albicans reduces murine susceptibility to Clostridium difficile infection.

Authors:  Laura Markey; Lamyaa Shaban; Erin R Green; Katherine P Lemon; Joan Mecsas; Carol A Kumamoto
Journal:  Gut Microbes       Date:  2018-05-30

Review 6.  Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections.

Authors:  Lynne Vernice McFarland; Metehan Ozen; Ener Cagri Dinleyici; Shan Goh
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

7.  Antibiotic susceptibility of Clostridium difficile is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich.

Authors:  Andrea C Büchler; Silvana K Rampini; Simon Stelling; Bruno Ledergerber; Silke Peter; Alexander Schweiger; Christian Ruef; Reinhard Zbinden; Roberto F Speck
Journal:  BMC Infect Dis       Date:  2014-11-26       Impact factor: 3.090

8.  Characteristics of patients with Clostridium difficile infection in Taiwan.

Authors:  Y-C Lin; Y-T Huang; T-F Lee; N-Y Lee; C-H Liao; S-Y Lin; W-C Ko; P-R Hsueh
Journal:  Epidemiol Infect       Date:  2012-12-06       Impact factor: 4.434

9.  Antimicrobial susceptibility of clostridium difficile clinical isolates in iran.

Authors:  Mehdi Goudarzi; Hossein Goudarzi; Masoud Alebouyeh; Masoumeh Azimi Rad; Farahnaz Sadat Shayegan Mehr; Mohammad Reza Zali; Mohammad Mehdi Aslani
Journal:  Iran Red Crescent Med J       Date:  2013-08-05       Impact factor: 0.611

10.  Clostridium difficile Infections in Medical Intensive Care Units of a Medical Center in Southern Taiwan: Variable Seasonality and Disease Severity.

Authors:  Jen-Chieh Lee; Yuan-Pin Hung; Hsiao-Ju Lin; Pei-Jane Tsai; Wen-Chien Ko
Journal:  PLoS One       Date:  2016-08-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.